Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A benign or malignant neoplasm arising from paraganglia located along the sympathetic or parasympathetic nerves. Infrequently, it may arise outside the usual distribution of the sympathetic and parasympathetic paraganglia. Tumors arising from the adrenal gland medulla are called pheochromocytomas. Morphologically, paragangliomas usually display a nesting (Zellballen) growth pattern. There are no reliable morphologic criteria to distinguish between benign and malignant paragangliomas. The only definitive indicator of malignancy is the presence of regional or distant metastases.
Biomarker and diagnostic research for paraganglioma has been reported in the published literature.
51 clinical trials registered, 29 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE4, 18 PHASE2, 6 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04119024](https://clinicaltrials.gov/study/NCT04119024) |
Data assembled from 3 of 12 sources · Last updated Nov 17, 2026, 6:42 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors |
PHASE1 |
Anusha Kalbasi |
RECRUITING |
[NCT04081701](https://clinicaltrials.gov/study/NCT04081701) | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. | PHASE4 | Weill Medical College of Cornell University | RECRUITING |
[NCT06683846](https://clinicaltrials.gov/study/NCT06683846) | Ivonescimab in the Treatment of Multiple Advanced Tumors | PHASE2 | Fudan University | RECRUITING |
[NCT07072143](https://clinicaltrials.gov/study/NCT07072143) | An International Study on Pediatric Patients With Rare Tumors. | — | Azienda Ospedaliera di Padova | RECRUITING |
[NCT06444607](https://clinicaltrials.gov/study/NCT06444607) | Hereditary Pheochromocytoma Assessment of Tumour Immunologies | — | Radboud University Medical Center | RECRUITING |
500 publications have been identified in PubMed for paraganglioma. Research spans Case Report / Case Series (29%), Review / Meta-Analysis (24%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 146 | 29% |
Research summaries | 120 | 24% |
Disease patterns and progression | 72 | 14% |
Laboratory research | 59 | 12% |
Testing and diagnosis research | 48 | 10% |
Clinical study results | 43 | 9% |
Other research | 7 | 1% |
New treatment approaches | 5 | 1% |
Bobadilla-Rosado LO (2026). [PMID: 41895584](https://pubmed.ncbi.nlm.nih.gov/41895584/). *Ann Vasc Surg*. [Epidemiology / Natural History]
Halperin R (2026). [PMID: 41783997](https://pubmed.ncbi.nlm.nih.gov/41783997/). *Eur J Endocrinol*. [Epidemiology / Natural History]
Wen JX (2026). [PMID: 41496095](https://pubmed.ncbi.nlm.nih.gov/41496095/). *Medicine (Baltimore)*. [Case Report / Case Series]
Satya Graha J (2026). [PMID: 42816107](https://pubmed.ncbi.nlm.nih.gov/42816107/). *BMJ Case Rep*. [Case Report / Case Series]
Belge Bilgin G (2026). [PMID: 41290367](https://pubmed.ncbi.nlm.nih.gov/41290367/). *J Nucl Med*. [Clinical Trial Publication]
Alesina PF (2026). [PMID: 41697281](https://pubmed.ncbi.nlm.nih.gov/41697281/). *Chirurgie (Heidelb)*. [Review / Meta-Analysis]
Hu ML (2026). [PMID: 42503923](https://pubmed.ncbi.nlm.nih.gov/42503923/). *Zhonghua Yi Xue Za Zhi*. [Epidemiology / Natural History]
Cubiella T (2026). [PMID: 41540233](https://pubmed.ncbi.nlm.nih.gov/41540233/). *Commun Biol*. [Basic Science / Preclinical]
Liu Y (2026). [PMID: 40705524](https://pubmed.ncbi.nlm.nih.gov/40705524/). *Clin Nucl Med*. [Case Report / Case Series]
Sun H (2026). [PMID: 42107147](https://pubmed.ncbi.nlm.nih.gov/42107147/). *Eur J Radiol*. [Epidemiology / Natural History]
AI-curated news mentioning paraganglioma
Updated Oct 11, 2026
A new case report highlights catecholamine-secreting retroperitoneal paraganglioma, contributing to the understanding of this rare tumor. The literature review provides insights into diagnosis and management strategies.
A case study highlights cardiac paraganglioma in a patient with SDHC-related hereditary paraganglioma pheochromocytoma syndrome. This research contributes to understanding the clinical manifestations of this rare genetic condition.
Recent research highlights belzutifan, a hypoxia-inducible factor 2-alpha inhibitor, as a potential treatment for patients with advanced pheochromocytoma and paraganglioma. This study contributes to the understanding of targeted therapies for these rare tumors.